leisure time -WSS

leisure time

author：hotspot 2025-09-27 22:06:15 - browse：8

Kara Coluccio, a managing partner at Perspective Group poses for a portrait. -- health coverage from STAT — Kara Coluccio, a managing partner at Perspective Group, says the job market for biotech executives has gotten much tighter. Jessica Rinaldi/Globe Staff

When Crystal Shih Byers left her job at Novartis in 2020, she was excited to make the leap into a smaller startup.

Byers had spent almost nine years at Novartis, most recently helping lead a group that worked on gene therapy. But pharmaceutical companies are large and complex, and she craved more immediate impact. “I was looking for a place where I could be in the room,” she says. She wanted more autonomy, and to feel like her work would reach patients sooner.

At the time, biotech startups were rolling in cash and seeking to capture some of the magic that had fueled Moderna’s meteoric rise. They handed out lots of logo-embossed swag. “Investors were putting a lot of money into stupid science,” Byers says. “There were a lot of companies that lasted for a lot longer than I thought they would on very little data.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Kidney transplant patients stopped immunosuppressants in trial

WSS

What is microchimerism and how does it affect maternal health?

Life sciences investors close nearly $6 billion in new funds

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

A new drug could help frostbite victims avoid its ravages

All of Us, NIH's precision medicine initiative, gets a big boost

Surprise medical billing ban raises prices elsewhere

explore

leisure time

leisure time

Guidelines to prevent youth baseball injuries need more muscle

MD Anderson's Padmanee Sharma responds to research credit suit

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare must police algorithms in Medicare Advantage, Dems say

Psychedelics group wrestles with new pharma identity

After Sarepta trial failure, Duchenne families brace for more debate

Trump demands the U.S. pay no more for drugs than other countries … again

What is microchimerism and how does it affect maternal health?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Inari Medical to buy amputation prevention company LimFlow

hotspot

As AI regulations shape up, health tech startups beg for clarity

Bill would allow buprenorphine prescription for addiction via telehealth

DeepMind touts AlphaFold's new skills as protein folding AI models face off

The health care issue Democrats can’t solve: hospital reform

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

How neuroscience research could help beat back brain cancer

leisure time

hotspot

Wikipedia

entertainment